Sign In
Buy BMY
$59.34
+1.76 (+3.06%)
At Close: Jul 13, 2026
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment
02:00pm, Monday, 13'th Jul 2026
The U.S. Food and Drug Administration (FDA) on Monday accepted the new drug application for Bristol Myers Squibb & Co.'s (NYSE:BMY) investigational oral therapy mezigdomide in combination with carfilz
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.
Start Investing At 60 And Retire On Dividends Forever
08:00am, Friday, 10'th Jul 2026
Retiring on dividends remains achievable for late starters by building a high-yield, quality portfolio targeting a 6% yield with safe, growing payouts. Dividend-focused strategies mitigate sequence of
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now
06:30pm, Tuesday, 07'th Jul 2026
They may not remain cheap for too much longer.
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)
10:45am, Tuesday, 07'th Jul 2026
AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.
Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.
04:44am, Monday, 06'th Jul 2026
Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. However, the company faces a daunting patent cliff.
Bristol Myers Squibb: Pain First, Payoff Later?
11:58pm, Friday, 03'rd Jul 2026
Bristol Myers Squibb remains a Strong Buy, supported by steady performance and undervaluation despite recent underperformance versus the benchmark. BMY boasts a 4.43% forward dividend yield, over 2.7x
Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes
09:25am, Friday, 03'rd Jul 2026
BMY's growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1'26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Wednesday, 01'st Jul 2026
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
07:30am, Wednesday, 01'st Jul 2026
Bristol Myers Squibb focuses on specialized medicines in oncology and immunology, and shares sport a low valuation. Johnson & Johnson offers a diversified business model spanning innovative medicines
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 30'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merck, AbbVie probed by US lawmakers over China clinical trials: report
08:19am, Tuesday, 30'th Jun 2026
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:45am, Tuesday, 30'th Jun 2026
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
06:46pm, Monday, 29'th Jun 2026
In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.56, marking a +1.81% move from the previous day.
66 With $1.3 Million. Here Are 3 Hidden Gems to Target
10:51am, Monday, 29'th Jun 2026
At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most
